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Dissent
To the Preceding Article by H. Hemilä
It is a pleasure, albeit a somewhat painful one, to respond to the
article by Hemilä criticizing our clinical trial of the prophylactic and
therapeutic use of ascorbic acid in the common cold. I am pleased
to have attention paid to the trial, 20 years after its publication,
because I am more proud of it than almost any other that I have
published. I am proud of it for essentially four reasons:
1. When I assumed directorship of the Clinical Center of the Na-
tional Institutes of Health (NIH) in 1970 I was anxious to estab-
lish my firm belief that all physicians engaged in practice and
administration should conduct research relatedjo their clinical
responsibilities. The Employee Health Department of the whole
NIH was under my jurisdiction, and the appearance of the late
Linus Pauling's book on vitamin C and the common cold (Ref.
9 in Hemilä's article) suggested a strong need for a well-designed
and conducted clinical trial, a nice challenge to an employee
health department. Dr. Thomas R. Karlowski was a Clinical As-
sociate in the Department who enthusiastically accepted the
challenge.
2. At the time where there was too little biostatistical input into
clinical trials in the design stage and we were fortunate to enlist
the collaboration of an experienced statistician in one of the In-
stitutes. When the breaking of the blind described below was
discovered, he withdrew and requested an anonymity that I have
respected because he considered that it was too flawed a study
to be published. I disagreed and felt strongly that we had a unique
opportunity to publicize a defect that probably occurs quite com-
monly, but had never been documented in the past. His impor-
tant contribution is illustrated by the unique stopping rules, a
most important part of clinical trials that is seldom acknowl-
edged. The protocol called for the study to be stopped before the
estimated necessary sample size was achieved if "(1) the dropout
rates from the group treated with ascorbic acid and the placebo
groups . . . were . . . significantly different (the level of signifi-
cance was to be taken at 0.15); (2) the number of persons under
study fell below 200; and (3) at six months from the beginning
of study the number of colds in the ascorbic acid treated group
was significantly greater than the number in the placebo group
(level of significance, 0.05)." The study was stopped 9 months
after the last subjects had entered, when both the number re-
maining dropped below the estimated minimal number of 200,
and it was apparent that more of the dropouts were in the placebo
group (p = 0.10). The wisdom of this move is obvious, and the
lesson for other studies is that there is a real advantage, one that
overwhelms any mythical disadvantage of multiple looks, of
monitoring trial results closely, with emphasis on the direction
of the trends as well as how they fit with other related studies.
3. The third aspect of the trial of which I am proud is the very one
that Hemilä attempts to criticize: that we did a routine check
on the blinding by obtaining answers to a questionnaire, and that
we recorded after interviews how many volunteers confessed to
cheating by opening the capsules and tasting the contents. In
any event Hemilä accuses us of assuming that if the volunteers
guessed correctly which group they were in that means that they
knew, which is obviously not the case. Hemilä repeatedly ignores
our stated caveat that the numbers were too small for reliable
retrospective analyses and we are castigated for attempting them
in an effort to shed some light on the fact that our study did
not confirm what seemed to be the popular conception. He is
infuriated by our conclusion that it might well be a popular mis-
conception.
4. As far as I know this was the first use of a 2-by-2 factorial design
to investigate prophylaxis and treatment in the same patients.
Since there was no suggestion of interaction we combined the
two prophylaxis and the two treatment groups to successfully an-
swer both questions with the same patients. Hemilä criticizes us
for combining groups without saying why. He apparently does
not understand what a 2-by-2 factorial design is.
There are many other improper "straw men" in this review and
a previous one he has published of our meta-analysis of the published
randomized control trials. For one we used capsules and not tablets
to reduce the likelihood of an unintentional breaking of the blind.
For another he writes as though we established a dose-response rela-
tionship by our 2-by-2 design, and no such conclusion can be drawn
from the data. It was not concluded by us that the apparent slight
and clinically minimal effect on severity of symptoms was "entirely
due to the placebo effect." When he quotes opposing views of the
efficacy of ascorbic acid as demonstrated by randomized controlled
trials (RCTs), the majority of reference numbers refer to his pub-
lished reviews and two editions of Pauling's book.
In summary, I resent the time that I have had to devote to this
author's biased defense of his late mentor's infatuation with ascorbic
acid. It may be that a properly done, unbiased, and updated meta-
analysis of the RCTs should be carried out, but I think it would be
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Chalmers comments that "Hemilä accuses us of assuming that if the
volunteers guessed correctly which group they were in that means
that they knew, which is obviously not the case." In the Methods
section of Karlowski's Journal of the American Medical Association
(JAMA) paper [1] it is stated that "a questionnaire was submitted
to each of the participants asking them to guess which substance they
had been taking. The results of the questionnaire (Table 2) made it
mandatory to perform the analyses both in toto as well as according
to the participants' impression as to what they were taking" (italics
mine). In Table 2 of the Karlowski paper there are 40 and 39 sub-
jects who correctly "suspected" their drug was ascorbic acid or pla-
cebo, respectively [1]. Table 4 of the same article is titled "Distribu-
tion of colds according to knowledge of capsule contents" (italics
mine) and in this table it is stated that the same 40 and 39 subjects
"knew" whether they were being administered ascorbic acid or pla-
cebo [1]. However, the authors did not say how they became con-
vinced in between Tables 2 and 4 that a subject actually knew the
treatment instead of merely suspecting. Table 6 lists the results for
the subgroup of "unblinded" subjects [1]. The term "unblinded" in-
dicates that the subjects genuinely knew their treatment, whereas
the Methods section implies that these are actually subjects that
gave a correct answer when asked to "guess" which capsules they
had been taking. In their conclusion the authors stated that [1]: "an
association between severity and duration of symptoms and knowl-
edge of the medication taken seems to have been clearly established"
(italics mine). Thus the JAMA paper itself suggests that the correct
answers on the questionnaire were interpreted by the authors as ac-
tual knowledge of the treatment, although a great proportion of the
correct answers could have been due to correct guesses, as pointed
out in my paper.
Chalmers claims that no conclusions on the dose-response rela-
tionship can be drawn from their study. This statement seems incon-
sistent with the JAMA paper [1], in which the authors commented
that "volunteers taking placebo had colds of a mean duration of 7.14
days, while those taking 3 gm of ascorbic acid had colds of a mean
duration of 6.59 days and those taking 6 gm had colds of a mean
duration of 5.92 days. Thus, each 3-gm increment of ascorbic acid
would appear to shorten the mean duration of a cold by approxi-
mately half a day." The authors thus explicitly paid attention to the
apparent dose dependence, and it seems that they implicitly consid-
ered the possibility that larger doses might have produced still
greater effects. They nonetheless discarded the notion of dose de-
pendence since they concluded from their subgroup analysis that
the observed differences were due to the placebo effect. If the pla-
cebo effect interpretation is to be rejected, as I suggest in my paper,
the apparent dose dependence becomes a relevant issue again.
There are numerous popular misconceptions about vitamins and
about nutrition in general. Nevertheless, the effect of vitamin C on
colds has been of great interest in the academic community also.
Kleijnen et al. [2,3] carried out a thorough literature search and
found 61 controlled trials related to the question of whether vitamin
C has effects on the common cold. In the early 1970s Pauling con-
cluded that 1 g/day prevents and alleviates colds [4], and since
then 21 placebo-controlled studies using regular high-dose vitamin
C supplementation ( 1 g/day) have been published [5]. These stud-
ies may be considered as tests of Pauling's hypothesis. It is clear that
Pauling overestimated the effects of vitamin C supplementation.
The incidence of the common cold has not been markedly reduced
in subjects administered vitamin C [5]. The effect on symptoms has
been less than Pauling supposed, even though consistent benefit has
been observed [5]. Still, vitamin C is safe even at high levels of
intake [6] and costs few cents per gram, so that even a modest effect
may be of practical importance. It would seem worthwhile to inves-
tigate in detail what the quantitative effects on colds are, and which
groups of people would benefit most. The clinical significance can
then be estimated more accurately. I do not think that either popu-
lar misconceptions or Pauling's overoptimism should hamper such
investigation.
HARRI HEMILÄ
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